Recombinant Human IL-11
- Known as:
- Recombinant Human Interleukin-11
- Catalog number:
- SJB01-04
- Product Quantity:
- 50μg/vial
- Category:
- -
- Supplier:
- Cytokin.
- Gene target:
- Recombinant Human IL-11
Related genes to: Recombinant Human IL-11
- Gene:
- IL11 NIH gene
- Name:
- interleukin 11
- Previous symbol:
- -
- Synonyms:
- IL-11, AGIF
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-06
- Date modifiied:
- 2016-10-11
Related products to: Recombinant Human IL-11
Related articles to: Recombinant Human IL-11
- Organismal aging involves several hallmark pathways, including chronic inflammation and metabolic dysfunction. However, the origin of age-related inflammation is incompletely understood. In a recent study published in Nature, Widjaja et al. show that blocking the age-related increase in IL-11 restores immune-metabolic homeostasis and extends healthspan and lifespan in mice. - Source: PubMed
Kim Hee-HoonDixit Vishwa Deep - Histone lysine lactylation (Kla) is a post-translational modification, and its role in tumor immune escape remains unclear. Here, we find that increased histone lactylation is associated with poor response to immunotherapy in head and neck squamous cell carcinoma (HNSCC). H3K9la is identified as a specific modification site in HNSCC. Using cleavage under targets and tagmentation analyses, interleukin-11 (IL-11) is identified as a downstream regulatory gene of H3K9la. IL-11 transcriptionally activates immune checkpoint genes through JAK2/STAT3 signaling in CD8 T cells. Additionally, IL-11 overexpression promotes tumor progression and CD8 T cell dysfunction in vivo. Moreover, IL11 knockdown reverses lactate-induced CD8 T cell exhaustion, and cholesterol-modified siIL11 restores CD8 T cell killing activity and enhances immunotherapy efficacy. Clinically, H3K9la positively correlates with IL-11 expression and unfavorable immunotherapy responses in patients. This study reveals the crucial role of histone lactylation in immune escape, providing insights into immunotherapy strategies for HNSCC. - Source: PubMed
Publication date: 2024/08/30
Wang RuijieLi ChuwenCheng ZhongyiLi MingyuShi JianboZhang ZhiyuanJin ShufangMa Hailong - Adipose-derived stem cells (ADSCs) comprise a promising therapy for osteoarthritis (OA). The therapeutic potential of ELIXCYTE, an allogeneic human ADSC (hADSC) product, was demonstrated in a phase I/II OA clinical trial. However, the exact mechanism underlying such effects is not clear. Moreover, studies suggest that interleukin-11 (IL-11) has anti-inflammatory, tissue-regenerative, and immune-regulatory functions. Our aim was to unravel the mechanism associated with the therapeutic effects of ELIXCYTE on OA and its relationship with IL-11. We cocultured ELIXCYTE with normal human articular chondrocytes (NHACs) in synovial fluid obtained from individuals with OA (OA-SF) to investigate its effect on chondrocyte matrix synthesis and degradation and inflammation by assessing gene expression and cytokine levels. NHACs exposed to OA-SF exhibited increased expression. However, coculturing ELIXCYTE with chondrocytes in OA-SF reduced expression in chondrocytes and downregulated and expression in ELIXCYTE. ELIXCYTE treatment elevated anti-inflammatory cytokine (IL-1RA, IL-10, and IL-13) levels, and the reduction in was positively correlated with IL-11 concentrations in OA-SF. These findings indicate that IL-11 in OA-SF might serve as a predictive biomarker for the ELIXCYTE treatment response in OA, emphasizing the therapeutic potential of ELIXCYTE to mitigate OA progression and provide insights into its immunomodulatory effects. - Source: PubMed
Publication date: 2024/08/02
Chen Yu-HsiuHung Yi-PeiChen Chih-YingChen Yi-TingTsai Tai-ChenYang Jui-JungWu Chia-Chun - Although aberrant activation of the KRAS and PI3K pathway alongside TP53 mutations account for frequent aberrations in human gastric cancers, neither the sequence nor the individual contributions of these mutations have been clarified. Here, we establish an allelic series of mice to afford conditional expression in the glandular epithelium of Kras;Pik3ca or Trp53 and/or ablation of Pten or Trp53. We find that Kras;Pik3ca is sufficient to induce adenomas and that lesions progress to carcinoma when also harboring Pten deletions. An additional challenge with either Trp53 loss- or gain-of-function alleles further accelerated tumor progression and triggered metastatic disease. While tumor-intrinsic STAT3 signaling in response to gp130 family cytokines remained as a gatekeeper for all stages of tumor development, metastatic progression required a mutant Trp53-induced interleukin (IL)-11 to IL-6 dependency switch. Consistent with the poorer survival of patients with high IL-6 expression, we identify IL-6/STAT3 signaling as a therapeutic vulnerability for TP53-mutant gastric cancer. - Source: PubMed
Publication date: 2024/08/09
Huber AnneAllam Amr HDijkstra ChristineThiem StefanHuynh JenniferPoh Ashleigh RKonecnik JoshuaJacob Saumya PBusuttil RitaLiao YangChisanga DavidShi WeiAlorro Mariah GForrow StephenTauriello Daniele V FBatlle EduardBoussioutas AlexWilliams David SBuchert MichaelErnst MatthiasEissmann Moritz F - Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges such as resistance to shear force damage, mucus penetration, cellular internalization, rapid lysosomal escape, and target protein expression. Here, we introduce the innovative "LOOP" platform with a four-step workflow to develop inhaled lipid nanoparticles specifically for pulmonary mRNA delivery. iLNP-HP08 featuring a high helper lipid ratio, acidic dialysis buffer, and excipient-assisted nebulization buffer, demonstrates exceptional stability and enhanced mRNA expression in the lungs. By incorporating mRNA encoding IL-11 single chain fragment variable (scFv), scFv@iLNP-HP08 effectively delivers and secretes IL-11 scFv to the lungs of male mice, significantly inhibiting fibrosis. This formulation surpasses both inhaled and intravenously injected IL-11 scFv in inhibiting fibroblast activation and extracellular matrix deposition. The HP08 system is also compatible with commercially available ALC0315 LNPs. Thus, the "LOOP" method presents a powerful platform for developing inhaled mRNA nanotherapeutics with potential for treating various respiratory diseases, including idiopathic pulmonary fibrosis. - Source: PubMed
Publication date: 2024/08/10
Bai XinChen QijingLi FengqiaoTeng YilongTang MaopingHuang JiaXu XiaoyangZhang Xue-Qing